NPHS2 Human
Nephrosis 2 Idiopathic Steroid-Resistant Human Recombinant
Cat. No.
BT749
Source
Escherichia Coli.
Synonyms
Nephrosis 2, Idiopathic, Steroid-Resistant (Podocin), PDCN, SRN1, Podocin, NPHS2.
Appearance
Filtered White lyophilized (freeze-dried) powder.
Purity
Greater than 95.0% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs 
In Stock 
Description
NPHS2 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain (Val125-Leu383) containing 269 amino acids including a 10 aa His tag at N-terminus. The total calculated molecular mass is 30.2kDa.
Product Specs
Introduction
The NPHS2 gene encodes podocin, a protein crucial for maintaining the glomerular filtration barrier in kidneys. Mutations in this gene lead to steroid-resistant nephrotic syndrome, a condition characterized by proteinuria and edema.
Description
This product consists of a non-glycosylated polypeptide chain of human NPHS2, spanning from amino acid Val125 to Leu383. It's expressed in E. coli and purified to a single band on SDS-PAGE. A 10 amino acid His tag is present at the N-terminus, resulting in a total calculated molecular weight of 30.2kDa.
Physical Appearance
The product appears as a white powder after lyophilization (freeze-drying) and filtration.
Formulation
To ensure stability, the NPHS2 protein was filtered through a 0.4 micrometer filter and subsequently lyophilized in a buffer consisting of 30mM acetate and 1mM dithiothreitol at a pH of 4.
Solubility
To prepare a working solution, it is recommended to reconstitute the lyophilized powder in 0.1M acetate buffer (pH 4.0) to achieve a concentration of approximately 0.5mg/ml. Allow sufficient time for complete dissolution. For use at higher pH values, dilute the stock solution with the appropriate buffer to a concentration of 10µg/ml. It's crucial to note that the solubility of this protein is limited at higher concentrations. For cell culture applications, ensure sterility by filtering the product through a sterile filter before use.
Stability
For long-term storage, store the lyophilized protein at -20°C. Once reconstituted, aliquot the protein to prevent repeated freeze-thaw cycles. While the reconstituted protein can be stored at 4°C for a limited period (approximately two weeks) without noticeable changes, it's recommended to use it promptly.
Purity
Analysis by SDS-PAGE confirms a purity greater than 95.0%.
Synonyms
Nephrosis 2, Idiopathic, Steroid-Resistant (Podocin), PDCN, SRN1, Podocin, NPHS2.
Source
Escherichia Coli.
Amino Acid Sequence
MKHHHHHHASVKVVQEYERV IIFRLGHLLP GRAKGPGLFF FLPCLDTYHK VDLRLQTLEI PFHEIVTKDM FIMEIDAICY YRMENASLLL SSLAHVSKAV QFLVQTTMKR LLAHRSLTEI LLERKSIAQD AKVALDSVTC IWGIKVERIE IKDVRLPAGL QHSLAVEAEA QRQAKVRMIA AEAEKAASES LRMAAEILSG TPAAVQLRYL HTLQSLSTEK PSTVVLPLPF DLLNCLSSPS NRTQGSLPFP SPSKPVEPLN PKKKDSPML.
Product Science Overview
Pathophysiology
The underlying cause of idiopathic steroid-resistant nephrotic syndrome (SRNS) is often linked to genetic mutations in podocyte-associated genes. These mutations can disrupt the normal function of podocytes, which are crucial for maintaining the glomerular filtration barrier in the kidneys . In about 10-30% of steroid-resistant patients, mutations in these genes can be detected . For the remaining cases, an undefined circulating factor of immune origin is assumed to play a role .
Clinical Presentation
Patients with SRNS typically present with:
Diagnosis
Treatment
Treatment of SRNS is challenging due to its heterogeneous etiology and frequent lack of remission with further immunosuppressive therapy. The management approach includes:
- Immunosuppressive agents: Such as calcineurin inhibitors (e.g., cyclosporine, tacrolimus) and rituximab.
- Supportive care: Including diuretics for edema, statins for dyslipidemia, and anticoagulants for hypercoagulable state .
- Renal transplantation: In cases where SRNS progresses to end-stage kidney disease .
Prognosis
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
